Drug Trial Radar · NCT04830449
Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients
Last checked: Nov 19, 2026Latest source record: Sep 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
122
Actual
Start
Oct 29, 2020
Primary completion
Aug 24, 2021
Study completion Aug 24, 2021
Sponsor
- Lead sponsor
- Hanmi Pharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Apr 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate of efficacy and safety of HCP1904-2 and RLD2001-2 alone in patients with essential hypertension inadequately controlled on RLD2001-2 monotherapy.
Conditions
- Hypertension
Interventions
HCP1904-2Drug
Take it once daily for 8 weeks orally.
RLD2001-2Drug
Take it once daily for 8 weeks orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in mean sitting systolic blood pressure(mmHg)Time frame: Week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Severance Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.